MGMT and glioblastoma: In glioblastoma, promoter hypermethylation of the DNA repair gene MGMT reduces DNA repair capacity, confers sensitivity to alkylating chemotherapy such as temozolomide, and remains one of the most robust predictive biomarkers in neuro-oncology (20).